DC ChemicalsChemicals for Life Science
sales@dcchemicals.com

DC82209 · Updated 24 October 2026

Lipid 10a-26
Formulation & Performance

This edition organizes the previously reviewed, source-linked product record. It is not a new independent review of every paper or supporting file. Reported and calculated values retain their original labels.

Literature-reported formulation composition

Componentmol%Role
Lipid 10a-26 / Lipid 2662Ionizable lipid
DSPC4Helper phospholipid
Cholesterol33Sterol
DSPE-PEG 20001PEG lipid
Reported total100Source values retained
Formulation calculator unavailable. The literature formulation can be displayed as a reported 16:1:4:1 weight ratio and patent-stated 62:4:33:1 molar ratio, but fixed quantitative weighing is disabled because DSPE-PEG 2000 batch MW and the patent's weight-to-molar conversion basis are not independently resolved. Obtain and verify the complete composition and component molecular weights before planning component quantities.
Not reported in the cited article
25 mM sodium acetate, pH 5.2 in the aqueous phase; post-formulation dialysis in 1 L water with two exchanges over 18 h; 0.2 µm filtration; diluted in PBS before dosing.
Circular RNA encoding firefly luciferase for organ-expression and biodistribution studies; separate circular RNA constructs were used for GFP, Cre and anti-CD19 CAR experiments.
Intravenous administration in mice for the in-vivo organ-expression experiments.
0.5 mg/kg RNA IV for Lipid 26 in Example 38; the patent also reports 0.2 mg/kg in other organ-expression examples, which are not assumed to be the same formulation.
Female CD-1 or C57BL/6J mice; Ai9 reporter mice for Cre-circRNA immune-cell transfection experiments.
Precision Nanosystems Ignite instrument with NextGen mixing chamber; aqueous:cargo phase to ethanol lipid phase mixing ratio 3:1.

Literature-reported performance for the cited formulation

Literature-reportedLipid 26 gave increased total flux and increased overall ex-vivo tissue expression versus Lipids 22-S14 and 93-S14 while retaining the desired spleen:liver expression relationship.FLuc circRNA LNP, IV mouse study · Lipid 22-S14 and Lipid 93-S14 LNPsWO2021189059A2 [0843]-[0844], Fig. 32A-B and Fig. 35A-B.
Literature-reportedLipid 26 LNPs supported circular-RNA expression in multiple splenic immune-cell subsets, including myeloid, B-cell and T-cell populations; the patent reports significantly higher myeloid and T-cell transfection than Lipid 93-S14.Cre circRNA in Ai9 mice · Lipid 93-S14 and PBS backgroundWO2021189059A2 [0861]-[0862], Fig. 45A-C.

Additional reported findings

Patent synthesis/identity context · WO2021189059A2 [0823]-[0824].
Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.

The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
Cited literature for this formulation and performance datasetWesselhoeft A, Goodman B, et al. Circular RNA compositions and methods. WO2021189059A2 (2021). DOI: https://patents.google.com/patent/WO2021189059A2/en
All quantitative claims apply to the cited Lipid 26 circRNA LNP experiments in mice, not to the neat lipid alone.